Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors
- 17 June 2008
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 105 (24), 8387-8392
- https://doi.org/10.1073/pnas.0803383105
Abstract
A subset of gastrointestinal stromal tumors (GISTs) lack gain-of-function mutations in c-KIT and PDGFRα. These so-called wild-type (WT) GISTs tend to be less responsive to imatinib-based therapies and have a poor prognosis. We identified amplification of IGF1R in a SNP analysis of GIST and thus studied its potential as a therapeutic target in WT and mutant GIST. Expression of IGF1R and downstream effectors in clinical GIST samples was examined by using immunoblots and immunohistochemistry. The roles of IGF1R signaling in GIST and viability were analyzed by using NVP-AEW541, an inhibitor of IGF1R, alone and in combination with imatinib, or via siRNA silencing of IGF1R. IGF1R was strongly overexpressed, and IGF1R amplification was detected at a significantly higher frequency in WT GISTs, including a pediatric WT GIST, compared with mutant GISTs (P = 0.0173 and P = 0.0163, respectively). Inhibition of IGF1R activity in vitro with NVP-AEW541 or down-regulation of expression with siIGF1R led to cytotoxicity and induced apoptosis in GIST cell lines via AKT and MAPK signaling. Combination of NVP-AEW541 and imatinib in GIST cell lines induced a strong cytotoxicity response. Our results reveal that IGF1R is amplified and the protein is overexpressed in WT and pediatric GISTs. We also demonstrate that the aberrant expression of IGF1R may be associated with oncogenesis in WT GISTs and suggest an alternative and/or complementary therapeutic regimen in the clinical management of all GISTs, especially in a subset of tumors that respond less favorably to imatinib-based therapy.This publication has 42 references indexed in Scilit:
- Early effects of imatinib mesylate on the expression of insulin‐like growth factor binding protein‐3 and positron emission tomography in patients with gastrointestinal stromal tumorCancer, 2006
- Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancerMolecular and Cellular Endocrinology, 2006
- Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: Major challenges in current practiceLeukemia & Lymphoma, 2006
- The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of ChemotherapyClinical Cancer Research, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal of Cancer, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002
- Prevention of cytokine-induced apoptosis by insulin-like growth factor-I is independent of cell adhesion molecules in HT29-D4 colon carcinoma cells–evidence for a NF-κB-dependent survival mechanismCell Death & Differentiation, 2002
- Gastric stromal tumors Reappraisal of histogenesisThe American Journal of Surgical Pathology, 1983